Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line
- J Chemother. 2016 Aug;28(4):314-20. doi: 10.1179/1973947815Y.0000000055.
- 1. a Department of Pharmacology, School of Medicine , Mashhad University of Medical Sciences , Iran.
- 2. b Pharmacological Research Center of Medicinal Plants, School of Medicine , Mashhad University of Medical Sciences , Iran.
- 3. c Medical Toxicology Research Center, School of Medicine , Mashhad University of Medical Sciences , Iran.
Objective: Over expression of renin-angiotensin system (Ras) and nuclear factor-kappaB (NF-kappaB) have major role in many cancers. In this study, role of angiotensin II (Ag II) and NF-kappaB pathway in breast Cancer cell line (MCF-7) proliferation were studied using olmesartan (as a novel Ag II antagonist) and Bay11-7082 (as NF-kappaB inhibitor).
Materials and methods: Cells were treated with different concentrations of olmesartan and Bay11-7082.Cell proliferation was determined by 4, 5-Dimethylthiazol-2-yl, 2, 5-diphenyl tetrazolium (MTT) assay. Apoptotic cells were evaluated using PI staining of DNA fragmentation.
Results: Olmesartan and Bay11-7082 decreased cell viability. Combination of olmesartan with Bay11-7082 also decreased cell viability as compared with single agent treatments. Results showed that Apoptosis is involved in olmesartan and Bay11-7082-induced toxicity.
Conclusion: Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating Ras and NF-kappaB pathway blockade lead to cytotoxicity and Apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as Anticancer drugs in future.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Angiotensin ReceptorResearch Areas: Cardiovascular Disease